Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

OBJECTIVES:

• Evaluation of feasibility of dendritic cell (DC)-based vaccination program using autologous tumor cells and/or lysates in patients with indolent B cell lymphomas or multiple myeloma as an adjuvant therapy to induce immune response in remission after cytoreductive treatment.
• Evaluation of the immune response of patients treated with this regimen.
• Evaluation the progression-free survival of patients treated this regimen.
• Evaluate the adverse events of this regimen in these patients.

OUTLINE: Patients receive intranodal (under ultrasound guidance) or subcutaneous vaccinations of adjuvant electrofusion hybrids of autologous dendritic cells (DC) with autologous lymphoma cells, electrofusion hybrids of allogeneic DC with autologous lymphoma cells, and/or autologous DC pulsed with autologous tumor lysate cells in weeks 0, 2, 4, 8, 12, 18, 26, and 50.

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of 1 of the following:

• Mantle cell lymphoma
• Marginal zone lymphoma
• Follicular lymphoma
• Small lymphocytic lymphoma/chronic lymphocytic leukemia
• Multiple myeloma
• Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia
• Diffuse large B-cell lymphoma
• Adequate sample size and lymphoma cell content in the fresh tissue collected
• No bulky or progressive disease

PATIENT CHARACTERISTICS:

• Life expectancy > 3 months
• No evidence of lung, heart, liver, or renal failure or severe neurologic disorder
• No autoimmune disease or atopic allergy
• No HIV positivity
• No other malignancy

PRIOR CONCURRENT THERAPY:

• Not specified